GKOS — Glaukos Corporation Stock Price, Chart & AI Report

Neutral Sep 4, 2025 • 05:30 UTC GlobeNewswire Inc. • Nicox Sa

Nicox prévoit de rembourser intégralement ses dettes financières, NCX 470 ayant été dé-risqué et licencié dans le monde entier

Nicox plans to fully repay its financial debts by 2026 after successfully licensing NCX 470 globally with Kowa and Ocumension Therapeutics, with New Drug Application submissions expected in the first half of 2026 in the US and later in China.

GKOS BLCO NCX 470 glaucoma drug licensing financial strategy ophthalmology

Sentiment note

Extended research agreement for NCX 1728 preclinical program with Nicox

Neutral Sep 4, 2025 • 05:30 UTC GlobeNewswire Inc. • Gavin Spencer

Nicox Expects to Fully Repay Financial Debts with NCX 470 De-Risked and Globally Licensed

Nicox anticipates fully repaying its financial debts in 2026 following successful NCX 470 clinical trials and global licensing deals with Kowa and Ocumension Therapeutics, with expected NDA submissions in the U.S. and China in H1 2026.

GKOS BLCO NCX 470 glaucoma ophthalmology NDA licensing

Sentiment note

Extended research agreement for NCX 1728 preclinical program

Positive Sep 11, 2024 • 18:20 UTC Benzinga • Zacks

Glaukos Stocks Rides on Strong Product Demand Amid Competition

Glaukos Corporation is focused on developing and commercializing surgical devices and pharmaceutical therapies for glaucoma treatment. The company's iStent product line and global glaucoma and Corneal Health franchises are performing well, despite competition and supply chain challenges. Glaukos is also advancing its pipeline, including iDose TREX, iDose ROCK, and iLution Travoprost.

GKOS DGX BSX Glaukos Corporation iStent iDose TREX iDose ROCK iLution Travoprost

Sentiment note

The article highlights Glaukos' strong product demand, successful execution across its global franchises, and advancement of its pipeline products, indicating a positive outlook for the company.

Positive Jul 16, 2024 • 14:30 UTC Zacks Investment Research • N/A

Will WATCHMAN Sales Aid Boston Scientific's (BSX) Q2 Earnings? - Zacks Investment Research

Boston Scientific Corporation is scheduled to report its Q2 2024 results on July 24. The company is expected to report revenue growth of around 11.7% and adjusted earnings of 58 cents per share. However, the company may face challenges from a challenging supply environment, rising costs, and healthcare staffing shortages.

BSX EYE GKOS TNDM Boston Scientific Corporation Q2 2024 earnings revenue growth adjusted earnings

Sentiment note

The article highlights Glaukos as a stock that has a good chance of beating earnings estimates, based on its positive Earnings ESP and Zacks Rank.

Positive Jul 16, 2024 • 14:06 UTC Investing.com • Emilio Ghigini

Truist lifts Glaukos shares target, highlights strong market position - Investing.com

Truist Securities has raised its price target for Glaukos Corporation shares to $141, citing the company's strong market position and the potential of its iDose product. The firm maintains a Buy rating on the stock.

GKOS Glaukos Corporation iDose Truist Securities price target

Sentiment note

Truist Securities has raised its price target for Glaukos shares, highlighting the company's strong market position and the potential of its iDose product.

Negative Jul 10, 2024 • 13:05 UTC Benzinga • Avi Kapoor

This Visa Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga

Top Wall Street analysts have downgraded their ratings on several companies, including Spotify, Visa, Helen of Troy, LegalZoom, and Glaukos, citing various reasons for their bearish outlook.

SPOT V HELE LZ analyst ratings downgrades Spotify Visa

Sentiment note

Citigroup analyst Joanne Wuensch downgraded Glaukos from Buy to Neutral and raised the price target.

Positive Jul 4, 2024 • 10:07 UTC GlobeNewswire Inc. • Researchandmarkets.Com

Global Ophthalmic Devices Market Analysis Report 2024-2032 Featuring Johnson & Johnson, Topcon, Canon, Alcon ... - GlobeNewswire

The global ophthalmic devices market is projected to grow from $6.79 billion in 2023 to $10.22 billion by 2032, driven by the increasing prevalence of eye conditions and technological advancements in diagnosis and treatment.

JNJ CAJPY ALC STAA ophthalmic devices vision care eye health market analysis

Sentiment note

The article mentions Glaukos Corporation as one of the key players in the ophthalmic devices market, suggesting their significant role and potential for growth in this sector.

Unknown Jun 27, 2024 • 16:49 UTC Zacks Investment Research • Zacks Equity Research

Glaukos (GKOS) Reaches 52-Week High: What's Driving the Stock?

Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.

ECL DVA LMAT GKOS

Unknown Jun 27, 2024 • 07:19 UTC Zacks Investment Research • Zacks Equity Research

Glaukos (GKOS) Stock Jumps 3.7%: Will It Continue to Soar?

Glaukos (GKOS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

GKOS TFX

Unknown Jun 6, 2024 • 15:31 UTC Zacks Investment Research • Zacks Equity Research

Why Is Waters (WAT) Down 5.1% Since Last Earnings Report?

Waters (WAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

WAT GKOS

Unknown Jun 5, 2024 • 16:14 UTC Zacks Investment Research • Zacks Equity Research

Glaukos (GKOS) Gains 40.4% YTD: What's Driving the Rally?

Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.

BSX ECL ALGN GKOS

Unknown Jun 3, 2024 • 17:53 UTC Zacks Investment Research • Zacks Equity Research

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

BSX ECL ALGN GKOS